Atlas Trials

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Clinical trial NCT00492050 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT00492050
Sponsor
M.D. Anderson Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Waldenstrom's Macroglobulinemia
Start date
2006-08-02
Primary completion
2021-02-28
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.